[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100575421":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":12,"centralContacts":25,"locations":31,"responsibleParty":52,"collaborators":12,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":12,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":12,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":34,"whyStopped":12,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Shandong University","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Healthy group","NO_INTERVENTION","The healthy group met the inclusion and exclusion criteria, and stool samples were retained for microflora analysis as control.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Patient group","EXPERIMENTAL","Patients were required to collect stool samples and score a psychopsychological questionnaire. After enrollment, patients were given Rifaximin dry suspension 0.4g bid for 2 weeks. During the medication period, patients' drug consumption and adverse reactions were recorded through diary cards. After 2 weeks of medication, diary cards and outer packaging of drugs were collected, and case report forms were supplemented. Stool samples were collected again, anxiety and depression scale scores were performed, and clinical symptom changes were recorded. The breath test was reviewed 1 month after the end of the medication, and follow-up was conducted 3 months and 6 months after the end of the medication.",[18],"Drug: Rifaximin (drug)",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":12},"DRUG","Rifaximin (drug)","Rifaximin 0.4g bid for 2 weeks",[14],[26],{"name":27,"role":28,"phone":29,"phoneExt":12,"email":30},"Xiuli Zuo, MD,PhD","CONTACT","15588818685","zuoxiuli@sdu.edu.cn",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Qilu Hospital of Shandong University","RECRUITING","Jinan","Shandong","250012","China","CN",{"type":41,"coordinates":42},"Point",[43,44],116.99722,36.66833,{"lat":44,"lon":43},[47,49],{"name":27,"role":28,"phone":48,"phoneExt":12,"email":30},"+8615588818685",{"name":50,"role":51,"phone":12,"phoneExt":12,"email":12},"xiaoqi Wu","PRINCIPAL_INVESTIGATOR",{"type":53,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"SPONSOR_INVESTIGATOR","Xiuli Zuo","Professor, Director of gastroenterology department of Qilu hospital.","100575421","efficacy-of-rifaximin-in-patients-with-small-intestinal-bacterial-overgrowth-presenting-with-abdominal-bloating-100575421",false,"NCT06772064","Efficacy of Rifaximin in Patients With Small Intestinal Bacterial Overgrowth Presenting With Abdominal Bloating.","Efficacy of Rifaximin in Patients With Small Intestinal Bacterial Overgrowth Presenting With Abdominal Bloating: An Exploratory Study.","Healthy Group\n\nInclusion Criteria:\n\n1. Age between 18 and 70 years, both genders included.\n2. No special gastrointestinal discomfort such as bloating or abdominal pain, regular bowel movements, and normal stool characteristics.\n3. Negative hydrogen\u002Fmethane breath test.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women.\n2. History of gastrointestinal malignancy or gastrointestinal surgery.\n3. Past diagnosis or suspicion of lactose intolerance.\n4. Confirmed extra-digestive system diseases such as urinary system (chronic kidney disease, etc.), immune system (scleroderma, etc.), nervous system (Parkinson's, etc.), endocrine system (diabetes, etc.).\n5. Abnormalities in professional anxiety and depression symptom rating scales.\n6. Use of antibiotics, probiotics within two weeks, endoscopic examination, or use of prokinetics, secretagogues, antifoaming agents, antispasmodics, opioids, antidepressants within one week.\n7. Those who cannot or are unwilling to sign an informed consent form.\n\nPatient Group:\n\nInclusion Criteria:\n\n1. Age between 18 and 70 years, both genders included.\n2. Chief complaints of abdominal bloating and\u002For distension; outpatients with abdominal bloating and\u002For distension more prominent than other symptoms.\n3. Positive hydrogen\u002Fmethane breath test.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women.\n2. History of gastrointestinal malignancy or gastrointestinal surgery.\n3. Past diagnosis or suspicion of lactose intolerance.\n4. Confirmed extra-digestive system diseases such as urinary system (chronic kidney disease, etc.), immune system (scleroderma, etc.), nervous system (Parkinson's, etc.), endocrine system (diabetes, etc.).\n5. Moderate to severe abnormalities in professional anxiety and depression symptom rating scales.\n6. Use of antibiotics, probiotics within two weeks, endoscopic examination, or use of prokinetics, secretagogues, antifoaming agents, antispasmodics, opioids, antidepressants within one week.\n7. Those who cannot or are unwilling to sign an informed consent form.",true,"ALL","18 Years","70 Years",{"count":68,"type":69},115,"ESTIMATED","INTERVENTIONAL",[72],"NA","Abdominal bloating is a common clinical symptom in the digestive system, with obscure origins and complex mechanisms. Its etiology can be attributed to organic diseases and various Functional Gastrointestinal Disorders (FGIDs). In recent years, the roles of Small Intestinal Bacterial Overgrowth (SIBO), Oral-Cecal Transit Time (OCTT), and gut microbiota dysbiosis in Functional Abdominal Bloating\u002FDistention (FAB\u002FD) have garnered increasing attention. Currently, there is a lack of diagnostic tests and effective treatment measures for patients with bloating. The hydrogen\u002Fmethane breath test is a safe, economical, and non-invasive examination recommended for diagnosing SIBO. Rifaximin, an antibiotic that acts exclusively in the intestines, has been widely validated for its efficacy in SIBO and in patients with SIBO co-occurring with Irritable Bowel Syndrome (IBS). However, research on the role of SIBO in the production of bloating symptoms and the extent to which rifaximin treatment of SIBO alleviates symptoms in clinical bloating patients is still lacking. This study aims to investigate the efficacy of rifaximin in patients with SIBO who primarily present with bloating. Exploring clinical treatment options for bloating provides a reference for its management. Furthermore, questionnaires on psychiatric symptoms and fecal microbiota analysis for patients with bloating-type SIBO can help clarify the etiology of bloating, offering a basis for the etiological treatment of bloating patients in the next steps.",[75],"SIBO",[75,77,78],"Abdominal bloating","Rifaximin","2025-05-13",{"date":81,"type":82},"2025-05-16","ACTUAL",{"date":84,"type":82},"2025-04-15",{"date":86,"type":69},"2025-12-01",{"name":54,"class":6},1]